This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CVS Health (CVS) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Aug 7, 6:46AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agilon Health (AGL), CVS Health (CVS) and Sarepta Therapeutics (SRPT).

Claim 55% Off TipRanks

Agilon Health (AGL)

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Agilon Health, with a price target of $112.00. The company’s shares closed last Wednesday at $107.85.

According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.9% and a 43.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Privia Health Group. ;'>

Currently, the analyst consensus on Agilon Health is a Hold with an average price target of $74.25, which is a -21.7% downside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

CVS Health (CVS)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on CVS Health, with a price target of $118.00. The company’s shares closed last Wednesday at $99.12.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 12.6% and a 61.7% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Pediatrix Medical Group, and Fresenius Medical Care. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $111.56 average price target, a 19.0% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $115.00 price target.

Sarepta Therapeutics (SRPT)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $19.00. The company’s shares closed last Wednesday at $15.93.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 13.5% and a 55.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.93 average price target, a 39.6% upside from current levels. In a report issued on July 27, Morgan Stanley also maintained a Hold rating on the stock with a $25.00 price target.

Read More on AGL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).